N-[(S)-phenyl(pyridin-2-yl)methyl]-1,3-benzoxazol-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: N-[(S)-phenyl(pyridin-2-yl)methyl]-1,3-benzoxazol-2-amine
• 化学式: C₁₉H₁₅N₃O
• 分子量: 301.3
• InChiKey: AAZDQWDFOHJPTG-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  51
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Sphinogosine-1 -phosphate receptor modulators for treatment of cardiopulmonary disorders
  申请人：The Scripps Research Institute

  公开号：US11034691B2

  公开（公告）日：2021-06-15

  The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.

  本发明提供了作为鞘氨醇-1-磷酸受体调节剂用于治疗心肺疾病的有效化合物，这些疾病包括高血压（包括恶性高血压）、心绞痛、心肌梗塞、心律失常、充血性心力衰竭、冠心病、动脉粥样硬化、心绞痛、心律失常、心肌病（包括肥厚性心肌病）、心力衰竭、心脏骤停、支气管炎、哮喘、慢性阻塞性肺病、囊肿性纤维化、咳嗽、肺气肿、胸膜炎、肺纤维化、肺炎、肺栓塞、肺动脉高压、间皮瘤、心室传导性疾病、哮喘、慢性阻塞性肺病、囊性纤维化、咳嗽、肺气肿、胸膜炎、肺纤维化、肺炎、肺栓塞、肺动脉高压、间皮瘤、心室传导异常、完全性心脏传导阻滞、成人呼吸窘迫综合征、败血症综合征、特发性肺纤维化、硬皮病、系统性硬化症、腹膜后纤维化、预防瘢痕疙瘩形成或肝硬化。
• SPHINOGOSINE-1-PHOSPHATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US20170217963A1

  公开（公告）日：2017-08-03

  The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.